Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer.
The treatment of metastatic prostate cancer patients refractory to androgen withdrawal and docetaxel therapy is currently discouraging and new therapeutic approaches are vastly needed. Here, we report a long-term remission over one year in a 68-year-old patient with metastatic docetaxel-refractory prostate cancer employing low-dose trofosfamide. The patient suffered from distant failure with several bone lesions and lymph node metastases depicted by a (11) C-Choline positron emission tomography/computerized tomography (PET/CT). After initiation of trofosfamide 100 mg taken orally once a day we observed a steadily decreasing PSA value from initial 46.6 down to 2.1 mug/L. The Choline-PET/CT was repeated after 10 months of continuous therapy and demonstrated a partial remission of the bone lesions and a regression of all involved lymph nodes but one. Taken together we found an astonishing and durable activity of the alkylating agent trofosfamide given in a metronomic fashion. We rate the side effects as low and state an excellent therapeutic ratio of this drug in our patient.
Greiner
Jochen
J
Department of Internal Medicine III, University of Ulm, Albert Einstein-Allee 23, 89081 Ulm, Germany.
Küfer
Rainer
R
Reske
Sven N
SN
Martin
Volker
V
Döhner
Hartmut
H
Ringhoffer
Mark
M
Cancer. 2007 Aug 1;110(3):556-63
17577218
Anticancer Res. 2006 Jan-Feb;26(1B):539-42
16739316
Cancer Invest. 2009 Feb;27(2):221-6
19235596
Anticancer Drugs. 2006 Sep;17(8):997-8
16940811
BMC Cancer. 2007 Apr 15;7:65
17433113
Am J Pathol. 1993 Aug;143(2):401-9
7688183
In Vivo. 2008 Nov-Dec;22(6):831-6
19181016
J Clin Invest. 2000 Apr;105(8):1045-7
10772648
Clin Prostate Cancer. 2004 Jun;3(1):54-61
15279692
N Engl J Med. 2004 Oct 7;351(15):1502-12
15470213
Eur J Cancer. 2003 May;39(7):881-90
12706356